Graves’ Ophthalmopathy – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Graves’ Ophthalmopathy – Drugs In Development, 2024 report and make more profitable business decisions.
Graves’ ophthalmopathy is an autoimmune condition where the thyroid gland mistakenly senses harmful cells and releases antibodies to combat them. Since there are no harmful cells, the released antibodies end up fusing with muscles in the eyes, causing the onset of Graves’ ophthalmopathy. Symptoms include eye redness, eye inflammation, eyelid retraction, and eye weakness. Treatment includes radioiodine therapy, anti-thyroid medications, and thyroid surgery.
The Graves’ Ophthalmopathy drugs in development market research report provide comprehensive information on the therapeutics under development for Graves’ Ophthalmopathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Graves’ Ophthalmopathy and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Graves' Ophthalmopathy | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 26 molecules, with 25 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Graves’ Ophthalmopathy therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Graves’ Ophthalmopathy pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Graves’ Ophthalmopathy treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Acelyrin IncadvanceCor GmbH
Argenx SE
Chinese People's Liberation Army
Chongqing Kerun Biopharm R & D Co Ltd
Crinetics Pharmaceuticals Inc
CSPC NBP Pharmaceutical Co Ltd
Enceladus Pharmaceuticals BV
Eye Bio Korea Co Ltd
GSK plc
H. Lundbeck AS
HanAll Biopharma Co Ltd
Hefei Starry Gene Biotechnology Co Ltd
Horizon Therapeutics Plc
Immunovant Inc
Innovent Biologics Inc
Jiangsu Hengrui Medicine Co Ltd
Lassen Therapeutics 1 Inc
Lirum Therapeutics Inc
Minghui Pharmaceutical (Shanghai) Co Ltd
Regeneron Pharmaceuticals Inc
RevOpsis Therapeutics Corp
Septerna Inc
Sling Therapeutics Inc
Suzhou Pro-Heal Pharmaceutical Technology Co Ltd
Tourmaline Sub Inc
Viridian Therapeutics Inc
Zenas BioPharma (USA) LLC
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Graves' Ophthalmopathy reports